Sanofi Hit By Plavix Generics In Japan, But China Solid
This article was originally published in PharmAsia News
Executive Summary
During its second quarter earnings announcement, Sanofi talked in detail about the outlook for its Japanese business, which is set to be affected by generic competition to blockbuster Plavix, and also explained its recently announced global business reorganization plan.